Guardant Health, Inc. (GH)

NASDAQ • Currency in USD

$56.80

+$0.23

+0.40%

Last Update: 11 Sept 2025, 20:00

$7.08B

Market Cap

-16.95

P/E Ratio (TTM)

—

Forward Dividend Yield

$20.14 - $68.00

52 Week Range

GH Stock Price Chart

Explore Guardant Health, Inc. interactive price chart. Choose custom timeframes to analyze GH price movements and trends.

GH Company Profile

Discover essential business fundamentals and corporate details for Guardant Health, Inc. (GH) to support your stock research and investment decisions.

Sector

Healthcare

Industry

Medical - Diagnostics & Research

IPO Date

4 Oct 2018

Employees

2.00K

Website

https://guardanthealth.com

CEO

Helmy Eltoukhy

Description

Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing LUNAR-2 test for the early detection of colorectal cancer in asymptomatic individuals eligible; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, and kits fulfillment related services to biopharmaceutical companies and medical institutions. The company was incorporated in 2011 and is headquartered in Redwood City, California.

GH Financial Timeline

Browse a chronological timeline of Guardant Health, Inc. corporate events including earnings releases, dividend announcements, and stock splits.

Upcoming earnings on 28 Apr 2026

Upcoming earnings on 18 Feb 2026

Upcoming earnings on 5 Nov 2025

EPS estimate is -$0.48.

Earnings released on 30 Jul 2025

EPS came in at -$0.44 surpassing the estimated -$0.52 by +15.38%, while revenue for the quarter reached $232.09M , missing expectations by -1.49%.

Earnings released on 30 Apr 2025

EPS came in at -$0.49 surpassing the estimated -$0.61 by +19.67%, while revenue for the quarter reached $203.47M , missing expectations by -3.77%.

Earnings released on 20 Feb 2025

EPS came in at -$0.62 surpassing the estimated -$0.75 by +17.33%, while revenue for the quarter reached $201.81M , beating expectations by +4.84%.

Earnings released on 6 Nov 2024

EPS came in at -$0.45 surpassing the estimated -$0.55 by +18.18%, while revenue for the quarter reached $191.48M , beating expectations by +1.30%.

Earnings released on 7 Aug 2024

EPS came in at -$0.48 surpassing the estimated -$0.57 by +15.79%, while revenue for the quarter reached $177.24M , beating expectations by +8.93%.

Earnings released on 9 May 2024

EPS came in at -$0.46 surpassing the estimated -$0.72 by +36.11%, while revenue for the quarter reached $168.49M , beating expectations by +11.82%.

Earnings released on 22 Feb 2024

EPS came in at -$1.58 falling short of the estimated -$0.93 by -69.89%, while revenue for the quarter reached $155.05M , beating expectations by +3.67%.

Earnings released on 6 Nov 2023

EPS came in at -$0.73 surpassing the estimated -$0.93 by +21.51%, while revenue for the quarter reached $143.03M , beating expectations by +4.12%.

Earnings released on 3 Aug 2023

EPS came in at -$0.67 surpassing the estimated -$1.25 by +46.40%, while revenue for the quarter reached $137.15M , beating expectations by +5.98%.

Earnings released on 9 May 2023

EPS came in at -$1.30 falling short of the estimated -$1.26 by -3.17%, while revenue for the quarter reached $128.71M , beating expectations by +9.17%.

Earnings released on 23 Feb 2023

EPS came in at -$1.36 surpassing the estimated -$1.40 by +2.86%, while revenue for the quarter reached $126.89M , beating expectations by +2.48%.

Earnings released on 3 Nov 2022

EPS came in at -$1.58 falling short of the estimated -$1.27 by -24.41%, while revenue for the quarter reached $117.40M , missing expectations by -0.29%.

Earnings released on 4 Aug 2022

EPS came in at -$2.25 falling short of the estimated -$1.25 by -80.00%, while revenue for the quarter reached $109.14M , beating expectations by +3.87%.

Earnings released on 5 May 2022

EPS came in at -$1.21 surpassing the estimated -$1.23 by +1.63%, while revenue for the quarter reached $96.10M , beating expectations by +0.35%.

Earnings released on 23 Feb 2022

EPS came in at -$0.89 surpassing the estimated -$1.13 by +21.24%, while revenue for the quarter reached $108.11M , beating expectations by +9.59%.

Earnings released on 4 Nov 2021

EPS came in at -$1.06 falling short of the estimated -$0.90 by -17.78%, while revenue for the quarter reached $94.78M , beating expectations by +0.87%.

Earnings released on 5 Aug 2021

EPS came in at -$0.96 falling short of the estimated -$0.87 by -10.34%, while revenue for the quarter reached $92.10M , beating expectations by +8.85%.

Earnings released on 6 May 2021

EPS came in at -$0.49 surpassing the estimated -$0.82 by +40.24%, while revenue for the quarter reached $78.67M , beating expectations by +6.66%.

Earnings released on 24 Feb 2021

EPS came in at -$0.94 falling short of the estimated -$0.44 by -113.64%, while revenue for the quarter reached $78.32M , beating expectations by +15.15%.

Earnings released on 5 Nov 2020

EPS came in at -$0.78 falling short of the estimated -$0.34 by -129.41%, while revenue for the quarter reached $74.57M , beating expectations by +1.09%.